Novartis to sell its stake in Roche to Roche for $20.7bn
Novartis, which has been a shareholder in Roche for more than 20 years, will sell its stake in the business to Roche for $20.7bn.
Novartis, which has been a shareholder in Roche for more than 20 years, will sell its stake in the business to Roche for $20.7bn.
Human papillomavirus (HPV) vaccines reduce cervical cancer rates by 87% in women who were offered the jab between the ages of 12-13, according to a study which analysed data from England's HPV vaccine program.
Clade Therapeutics has raised US$87m in a Series A led by Syncona Ltd with participation from LifeSci Venture Partners, Emerson Collective and Bristol Myers Squibb (BMS).
Lonza has been investing in developing exosome manufacturing and characterization technologies for the past five years, and this week it ramped up its focus on that category by acquiring two sites.